{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:58:01Z","timestamp":1791622681890,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10072-025-08098-7","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T15:40:07Z","timestamp":1743867607000},"page":"3469-3476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Mahsa","family":"Ghajarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Rastkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-2003","authenticated-orcid":false,"given":"Bardia","family":"Nourbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"1","key":"8098_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ncl.2023.06.004","volume":"42","author":"NB Rjeily","year":"2024","unstructured":"Rjeily NB, Mowry EM, Ontaneda D, Carlson AK (2024) Highly effective therapy versus escalation approaches in early multiple sclerosis: what is the future of multiple sclerosis treatment? Neurol Clin 42(1):185\u2013201","journal-title":"Neurol Clin"},{"issue":"3","key":"8098_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England J Med 376(3):209\u201320","journal-title":"New England J Med"},{"issue":"3","key":"8098_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England J Med 376(3):221\u201334","journal-title":"New England J Med"},{"key":"8098_CR4","doi-asserted-by":"publisher","first-page":"104153","DOI":"10.1016\/j.msard.2022.104153","volume":"68","author":"J Weberpals","year":"2022","unstructured":"Weberpals J, Roumpanis S, Barer Y, Ehrlich S, Jessop N, Pedotti R et al (2022) Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre-and post-SARS-Cov-2 vaccination periods: Insights from Israel. Multiple Sclerosis Relat Disord 68:104153","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"14","key":"8098_CR5","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A et al (2020) Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology 95(14):e1999\u2013e2008","journal-title":"Neurology"},{"issue":"2","key":"8098_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184\u201391","journal-title":"JAMA Neurol"},{"issue":"5","key":"8098_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/13524585211055593","volume":"28","author":"L Rolfes","year":"2022","unstructured":"Rolfes L, Meuth SG (2022) Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing\u2014\u201cYes.\u201d Multiple Sclerosis J 28(5):691\u20133","journal-title":"Multiple Sclerosis J"},{"key":"8098_CR8","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"8098_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u20135","journal-title":"Eur J Epidemiol"},{"key":"8098_CR10","doi-asserted-by":"crossref","unstructured":"Meng D, Sacco R, Disanto G, Widmer F, Jacober SLS, Gobbi C et al (2024) Memory B cell\u2013guided extended interval dosing of ocrelizumab in multiple sclerosis. Mult Scler J 30(7):857\u2013867","DOI":"10.1177\/13524585241250199"},{"issue":"7","key":"8098_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/13524585241245296","volume":"30","author":"F Novak","year":"2024","unstructured":"Novak F, Bajwa HM, \u00d8stergaard K, Berg JM, Madsen JS, Olsen DA et al (2024) Extended interval dosing with ocrelizumab in multiple sclerosis. Multiple Sclerosis J 30(7):847\u201356","journal-title":"Multiple Sclerosis J"},{"key":"8098_CR12","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.msard.2023.105028","volume":"79","author":"T Rempe","year":"2023","unstructured":"Rempe T, Elfasi A, Rodriguez E, Vasquez M, Graves J, Kinkel R (2023) Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing\u2013similar clinical efficacy with decreased immunoglobulin M deficiency rates. Multiple Sclerosis Relat Disord 79:105028","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"10","key":"8098_CR13","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.3390\/ijms25105353","volume":"25","author":"M Nasello","year":"2024","unstructured":"Nasello M, Zancan V, Rinaldi V, Marrone A, Reni\u00e8 R, Diamant S et al (2024) Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience. Int J Mol Sci 25(10):5353","journal-title":"Int J Mol Sci"},{"key":"8098_CR14","doi-asserted-by":"publisher","first-page":"103287","DOI":"10.1016\/j.msard.2021.103287","volume":"56","author":"NK Sahi","year":"2021","unstructured":"Sahi NK, Abidi SMA, Salim O, Abraham R, Kalra S, Al-Araji A (2021) Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation. Multiple Sclerosis Relat Disord 56:103287","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"5","key":"8098_CR15","first-page":"e1035","volume":"8","author":"L Rolfes","year":"2021","unstructured":"Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R et al (2021) Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol: Neuroimmunol Neuroinflammation. 8(5):e1035","journal-title":"Neurol: Neuroimmunol Neuroinflammation."},{"issue":"9","key":"8098_CR16","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1111\/ene.15891","volume":"30","author":"S Guerrieri","year":"2023","unstructured":"Guerrieri S, Bucca C, Nozzolillo A, Genchi A, Zanetta C, Cetta I et al (2023) Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience. Eur J Neurol 30(9):2859\u201364","journal-title":"Eur J Neurol"},{"issue":"1","key":"8098_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","volume":"20","author":"C Rodriguez-Mogeda","year":"2023","unstructured":"Rodriguez-Mogeda C, van Lierop ZY, van der Pol SM, Coenen L, Hogenboom L, Kamermans A et al (2023) Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis. J Neuroinflammation 20(1):215","journal-title":"J Neuroinflammation"},{"issue":"6","key":"8098_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","volume":"4","author":"A Schuckmann","year":"2023","unstructured":"Schuckmann A, Steffen F, Zipp F, Bittner S, Pape K (2023) Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis. Medical 4(6):361\u201372.e3","journal-title":"Medical"},{"issue":"2","key":"8098_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1570159X22666231002142709","volume":"22","author":"A Zangh\u00ec","year":"2024","unstructured":"Zangh\u00ec A, Ferraro D, Callari G, Valentino P, Granella F, Patti F et al (2024) Ocrelizumab extended interval dosing in primary progressive multiple sclerosis: an Italian experience. Curr Neuropharmacol 22(2):339\u201345","journal-title":"Curr Neuropharmacol"},{"key":"8098_CR20","unstructured":"Allen C, Garjani A, Abdel-Fahim R, Russell M, Law G, Ford H, et al., editors. Disease activity and CD19+ B-cell counts with extended interval dosing of ocrelizumab. Multiple sclerosis journal; 2021: sage publications ltd 1 olivers yard, 55 city road, london ec1y 1sp, england"},{"key":"8098_CR21","doi-asserted-by":"crossref","unstructured":"Allen C, Russell M, Pendlebury J, Vollmer B, Moswela O, Raza P-T et al (2022) Extended interval dosing of ocrelizumab reduces risk of developing hypogammaglobulinaemia. BMJ Publishing Group Ltd","DOI":"10.1136\/jnnp-2022-abn2.26"},{"issue":"2","key":"8098_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-023-12084-4","volume":"271","author":"A Bisecco","year":"2024","unstructured":"Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F et al (2024) COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients. J Neurol 271(2):699\u2013710","journal-title":"J Neurol"},{"issue":"7","key":"8098_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1177\/13524585211028833","volume":"28","author":"ZY van Lierop","year":"2022","unstructured":"van Lierop ZY, Toorop AA, van Ballegoij WJ, OldeDubbelink TB, Strijbis EM, de Jong BA et al (2022) Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Multiple Sclerosis J 28(7):1121\u20135","journal-title":"Multiple Sclerosis J"},{"issue":"5","key":"8098_CR24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","volume":"19","author":"A Zangh\u00ec","year":"2022","unstructured":"Zangh\u00ec A, Avolio C, Signoriello E, Abbadessa G, Cellerino M, Ferraro D et al (2022) Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics. 19(5):1535\u201345","journal-title":"Neurotherapeutics."},{"key":"8098_CR25","doi-asserted-by":"publisher","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","volume":"44","author":"D Baker","year":"2020","unstructured":"Baker D, Pryce G, James LK, Marta M, Schmierer K (2020) The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Multiple Sclerosis Relat Disorde 44:102279","journal-title":"Multiple Sclerosis Relat Disorde"},{"key":"8098_CR26","doi-asserted-by":"crossref","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. (2022) Rituximab for the treatment of multiple sclerosis: a review. Journal of neurology. 1-25","DOI":"10.1007\/s00415-020-10362-z"},{"key":"8098_CR27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","volume":"268","author":"M Boremalm","year":"2021","unstructured":"Boremalm M, Sundstr\u00f6m P, Salzer J (2021) Discontinuation and dose reduction of rituximab in relapsing\u2013remitting multiple sclerosis. J Neurol 268:2161\u20138","journal-title":"J Neurol"},{"key":"8098_CR28","doi-asserted-by":"crossref","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS (2016) Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73(7):790\u2013794","DOI":"10.1001\/jamaneurol.2016.0826"},{"key":"8098_CR29","doi-asserted-by":"publisher","first-page":"101468","DOI":"10.1016\/j.msard.2019.101468","volume":"37","author":"A Juto","year":"2020","unstructured":"Juto A, Fink K, Al Nimer F, Piehl F (2020) Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Multiple Sclerosis Relat Disord 37:101468","journal-title":"Multiple Sclerosis Relat Disord"},{"issue":"5","key":"8098_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1212\/01.wnl.0000341783.33962.5b","volume":"72","author":"N Schiess","year":"2009","unstructured":"Schiess N, Calabresi PA (2009) Natalizumab: bound to rebound? Neurol 72(5):392\u20133","journal-title":"Neurol"},{"issue":"1","key":"8098_CR31","first-page":"e200056","volume":"10","author":"C StarvaggiCucuzza","year":"2022","unstructured":"StarvaggiCucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M et al (2022) Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol: Neuroimmunol Neuroinflammation 10(1):e200056","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"issue":"5","key":"8098_CR32","first-page":"e825","volume":"7","author":"A Maarouf","year":"2020","unstructured":"Maarouf A, Rico A, Boutiere C, Perriguey M, Demortiere S, Pelletier J et al (2020) Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol: Neuroimmunol Neuroinflammation 7(5):e825","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"issue":"5","key":"8098_CR33","first-page":"e200152","volume":"10","author":"R Claverie","year":"2023","unstructured":"Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P et al (2023) Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing? Neurol: Neuroimmunol Neuroinflammation 10(5):e200152","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"issue":"3","key":"8098_CR34","first-page":"e200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S (2024) Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol: Neuroimmunol Neuroinflammation 11(3):e200211","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"key":"8098_CR35","doi-asserted-by":"crossref","unstructured":"Freedman MS, Gnanapavan S, Booth RA, Calabresi PA, Khalil M, Kuhle J, et al. (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 101","DOI":"10.1016\/j.ebiom.2024.104970"},{"issue":"2","key":"8098_CR36","first-page":"e200094","volume":"10","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Bar-Or A, Weber MS, Kletzl H, G\u00fcnther A, Manfrini M et al (2023) Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol: Neuroimmunol Neuroinflammation 10(2):e200094","journal-title":"Neurol: Neuroimmunol Neuroinflammation"},{"key":"8098_CR37","doi-asserted-by":"crossref","unstructured":"BouRjeily N, Fitzgerald KC, Mowry EM (2024) Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity. Mult Scler J 30(2):257\u2013260","DOI":"10.1177\/13524585231208311"},{"issue":"2","key":"8098_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1570159X22666231002142709","volume":"22","author":"A Zangh\u00ec","year":"2023","unstructured":"Zangh\u00ec A, Ferraro D, Callari G, Valentino P, Granella F, Patti F et al (2023) Ocrelizumab extended interval dosing in primary progressive multiple sclerosis: an Italian experience. Curr Neuropharmacol 22(2):339","journal-title":"Curr Neuropharmacol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08098-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:00:18Z","timestamp":1757149218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["8098"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08098-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Bardia Nourbakhsh and Ellen Mowry received research funding from Genentech, unrelated to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}